Cipla introduces 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India
RT-Direct test protocol does not require any RNA extraction process, making it faster and helps deliver results in just 45 minutes.;
Advertisement
Mumbai: Pharma major, Cipla Limited, today announced the commercialisation of 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India, in partnership with Genes2Me Pvt. Ltd.
With this Cipla is expanding its diagnostics offering to bring more advance and innovative products. Cipla will be responsible for the distribution of RT Direct kits in India and has commenced supply of the same.
This kit is validated at the Indian Council of Medical Research (ICMR) approved Centre.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.